PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
J Neurosci. Author manuscript; available in PMC 2012 April 26.
Published in final edited form as:
PMCID: PMC3225957
NIHMSID: NIHMS336353

Impaired β-amyloid secretion in Alzheimer’s disease pathogenesis

Abstract

A central question in Alzheimer’s disease (AD) research is what role β-amyloid peptide (Aβ) plays in synaptic dysfunction. Synaptic activity increases Aβ secretion, potentially inhibiting synapses, but also decreases intraneuronal Aβ, protecting synapses. We now show that levels of secreted Aβ fall with time in culture in neurons of AD-transgenic mice, but not wild-type neurons. Moreover, the ability of synaptic activity to elevate secreted Aβ and reduce intraneuronal Aβ becomes impaired in AD-transgenic but not wild-type neurons with time in culture. We demonstrate that synaptic activity promotes an increase in the Aβ-degrading protease neprilysin at the cell surface and a concomitant increase in co-localization with Aβ42. Remarkably, AD-transgenic but not wild-type neurons show reduced levels of neprilysin with time in culture. This impaired ability to secrete Aβ and reduce intraneuronal Aβ has important implications for the pathogenesis and treatment of AD.

Introduction

A defining neuropathological feature of Alzheimer’s disease (AD) is the aberrant accumulation of β-amyloid peptide (Aβ). Aβ accumulation can lead to alterations in synapses and memory (Selkoe, 2002; Almeida et al., 2005; Hsieh et al., 2006). The site(s) and mechanism(s) whereby Aβ initiates dysfunction of synapses in AD are of major interest. Secreted, extracellular Aβ has traditionally been viewed as the source of Aβ- induced toxicity to synapses in AD, since addition of Aβ1-42 impairs synaptic function (Cleary et al., 2005; Shankar et al., 2008). On the other hand, picomolar levels of extracellular Aβ were recently shown to enhance synaptic plasticity (Puzzo et al., 2008). Remarkably, synaptic activity increases levels of secreted, extracellular Aβ (Kamenetz et al., 2003; Cirrito et al., 2005). Since the default network of the brain is particularly prone to the development of AD, it has been hypothesized that brain regions with the highest baseline metabolic activity are prone to AD because of high amounts of secreted Aβ (Cirrito et al., 2008; Palop and Mucke, 2010). However, it is unclear why such elevated levels of secreted Aβ from default network activity cause problems only with aging. Moreover, at risk individuals for AD show reduced brain activity decades prior to clinical symptoms (Reiman et al., 2004), which might predict for them to have reduced Aβ secretion. There is increasing support for an alternative scenario focusing on aberrant intracellular accumulation of Aβ within vulnerable neurons (Gouras et al., 2010). In fact, we recently demonstrated that Aβ-related synapse damage and memory impairment in AD-transgenic mice correlated with this intracellular pool of Aβ but not with plaques (Tampellini et al., 2010).

We now provide evidence for reduced Aβ secretion with time in culture in AD-transgenic but not wild-type neurons. Furthermore, we show that synaptic activity is able to reduce levels of intracellular Aβ in AD-transgenic neurons at 12 but not at 19 days in vitro (DIV). We demonstrate that levels of neprilysin are reduced in AD-transgenic but not wild-type neurons with time in culture. Finally, we provide mechanistic evidence consistent with neprilysin leading to degradation of Aβ42 at the cell surface with synaptic activity.

Materials and Methods

Neuronal cultures

Primary neuronal cultures were prepared from cortices and hippocampi of embryonic day 15 (E15) Tg2576 (AD-transgenic; Hsiao et al., 1996) and wild-type littermate mouse embryos as described (Tampellini et al., 2009). Tg2576 male and wild-type female mice (Jackson Laboratories) were bred to generate the embryos. Mice were used in accordance with the NIH Guide for the Care and Use of Laboratory Animals.

Antibodies

Immunofluorescence: neprilysin (H-321; Santa Cruz Biotechnology), early endosomal antigen-1 (EEA1; BD Transduction Laboratories), tumor susceptibility gene 101 (Tsg101; GeneTex), amyloid precursor protein (APP) intracellular domain (AICD; Covance), post-synaptic density-95 (PSD-95; Millipore), Aβ42 (C-terminus; Covance). Western blot: human specific Aβ/APP 6E10 (Covance), murine and human Aβ/APP 4G8 (Covance), rabbit polyclonal APP (C-terminus) 369, phospho-CaMKII (Millipore), total CaMKII (Millipore). Secondary antibodies were conjugated to Alexa Fluor-488 or -546 (Invitrogen) or horseradish peroxidase (Amersham Biosciences).

Treatments

For glycine-induced long term potentiation (g-LTP), neurons were treated as described (Tampellini et al., 2009). In experiments on neprilysin and Aβ42 surface colocalization during g-LTP stimulation, 50 M thiorphan was added to neurons during the 15 min incubation with or without glycine and then during the following 1 h chase to prevent Aβ degradation.

ELISA analysis

To measure Aβ secretion from primary neurons (6 cm dish) at steady state, media were replaced with 1 ml of fresh neurobasal medium and collected after 5 h. To measure Aβ secretion with or without g-LTP, LTP buffer was collected after the 1 h chase. Concentrations of Aβ1-40 and Aβ1-42 were measured using the respective ELISA kits (Biosource) for mouse (wild-type neurons) or human (AD-transgenic neurons) Aβ.

Western blot

Neuron lysates were prepared as described (Tampellini et al., 2009). Membranes were immunoblotted with antibodies 6E10 or 369, and intensities were quantified using Scion Image software (NIH).

Immunofluorescence

Immunofluorescence and its quantification were performed as described (Tampellini et al., 2009). Localization of surface neprilysin with Aβ42 and subcellular markers was determined using a colocalization algorithm (Leica Application Suite 1.8.2 software). To count AICD positive nuclei, all nuclei were marked with Hoechst stain. Counts of AICD positive and total nuclei were performed with Metamorph on 6 to 10 fields per coverslip at 20x magnification.

Statistical analysis

Statistical comparisons were made using two-tailed unpaired t tests with significance placed at p < 0.05.

Results

We previously reported progressive intraneuronal Aβ42 accumulation, alterations in endosomal trafficking, and AD-like synapse alterations in AD-transgenic neurons with time in culture, analogous to changes seen in vivo in AD-transgenic mouse brains with aging (Takahashi et al., 2004; Almeida et al., 2005; Almeida et al., 2006). We now examined whether time in culture affects Aβ secretion in AD-transgenic neurons. In wild- type neurons, levels of secreted Aβ1-40 and Aβ1-42 remained unchanged between 12 and 19 DIV (Figure 1A, left panels). In contrast, in AD-transgenic neurons, levels of secreted Aβ1-40 and Aβ1-42 fell by 33±4% and 39±9%, respectively, between 12 and 19 DIV (Figure 1A, right panels). We next examined levels of intraneuronal Aβ with time in culture. There was a 46±17% increase in levels of intraneuronal Aβ42 in AD-transgenic neurites at 19 compared to 12 DIV as quantified by confocal immunofluorescence microscopy (Figure 1B). In contrast, levels of intraneuronal Aβ42 were unchanged in wild-type neurons at 19 compared to 12 DIV (Figure 1C, D). Interestingly, the levels of APPα C-terminal fragments (αCTFs) fell by 52±2% between 12 and 19 DIV in AD- transgenic neurons, whereas levels of APPβ C-terminal fragments (βCTFs) and full- length APP remained unchanged (Figure 1E, left panels). Thus, amyloidogenic processing of APP, as reflected by the βCTF/αCTF ratio, increased approximately two- fold from 12 to 19 DIV in AD-transgenic neurons. Levels of αCTFs and βCTFs were both comparably decreased in wild-type neurons at 19 compared to 12 DIV (Figure 1E, right panels), and therefore the βCTF/αCTF ratio did not change.

Figure 1
Decreased Aβ secretion in AD-transgenic but not wild-type neurons with time in culture. (A) Levels of Aβ1-40 and Aβ1-42 were assayed by ELISA in media of AD-transgenic or wild-type neurons. While wild-type neurons secrete comparable ...

It has been shown that Aβ secretion is enhanced by synaptic activation (Kamenetz et al., 2003; Cirrito et al., 2005; Tampellini et al., 2009). Given the fall in steady-state secretion of Aβ in AD-transgenic neurons with time in culture, we investigated whether Aβ secretion was impaired during synaptic activity in AD-transgenic neurons with time in culture. Glycine-induced long-term potentiation (g-LTP) was used to stimulate neurons (Ehlers, 2003) at 12 and 19 DIV followed by Aβ ELISA of the conditioned media. We previously demonstrated that g-LTP increased Aβ secretion in AD-transgenic neurons at 12 DIV (Tampellini et al., 2009). We now show that while g-LTP increases Aβ secretion in wild-type neurons at 19 DIV, it failed to increase Aβ secretion in AD-transgenic neurons at 19 DIV (Figure 1F).

We reported that synaptic activation reduced intracellular Aβ42 and restored levels of PSD-95 back to wild-type levels in AD-transgenic neurons at 12 DIV (Tampellini et al., 2009). To investigate whether these effects are modulated by aging in vitro, we now induced g-LTP in 19 DIV AD-transgenic neurons and quantified levels of intraneuronal Aβ and PSD-95. At 19 DIV, g-LTP reduced levels of intraneuronal Aβ42 by 23±4% in wild-type neurons, but there was no decrease in AD-transgenic neurons as determined by confocal immunofluorescence (Figure 2A). These data were confirmed by ELISA (Figure 2B) and western blot (Figure 2C) of neuronal lysates. We confirmed that 12 DIV lysates showed decreased levels of intraneuronal Aβ in g-LTP treated compared to untreated AD-transgenic neurons (Figure 2C; lanes 1 and 2, longer exposure). Activity-induced reduction in levels of intraneuronal Aβ had promoted recovery of PSD- 95 puncta to wild-type levels in AD-transgenic neurons at 12 DIV (Tampellini et al., 2009). In contrast, levels of PSD-95 did not recover back to wild-type levels in g-LTP treated compared to untreated 19 DIV AD-transgenic neurons (Figure 2D), although there was still an increase compared to untreated AD-transgenic neurons.

Figure 2
Impaired ability for synaptic activity to reduce intraneuronal Aβ42 and protect synapses in AD-transgenic neurons with time in culture. (A) g-LTP reduced levels of intraneuronal Aβ42 by 23±4% in wild-type (left panels) but not ...

We showed that activity-dependent reduction in intraneuronal Aβ is dependent on the Aβ-degrading protease neprilysin (Tampellini et al., 2009). Data on the subcellular localization of neprilysin showed marked relative colocalization of neprilysin predominantly with late endosomes (Figure 2E). To investigate the mechanism of neprilysin-dependent Aβ42 clearance with synaptic activity, levels of neprilysin were quantified as a function of synaptic activation. g-LTP did not change total levels of neprilysin (not shown), however, it increased levels of surface neprilysin by 37±7% in stimulated compared to unstimulated wild-type neurons (Figure 3A). Surface neprilysin also increased in stimulated compared to unstimulated AD-transgenic neurons (Figure 3B). We next explored whether the increased localization of neprilysin to the cell surface could be responsible for the augmented neprilysin-dependent Aβ42 degradation. To test this hypothesis, g-LTP was induced in AD-transgenic neurons in the presence of the neprilysin inhibitor thiorphan to prevent loss of Aβ42 labeling from degradation. g-LTP increased the relative colocalization of neprilysin with Aβ42 at the cell surface by 54±21% (Figure 3C).

Figure 3
Synaptic activation increases neprilysin surface levels and colocalization with Aβ42. (A) g-LTP increased levels of surface neprilysin by 37±7% in g-LTP treated compared to untreated wild-type neurons at 12 DIV (n=6; p<0.01; scale ...

Since synaptic activation failed to reduce levels of intraneuronal Aβ in AD- transgenic neurons at 19 DIV, we next investigated whether levels of neprilysin were altered in AD-transgenic neurons with time in culture. Remarkably, levels of neprilysin were decreased by 18±8% in 19 compared to 12 DIV AD-transgenic but not wild-type neurons, as quantified by confocal immunofluorescence (Figure 4A). Previous work reported that neprilysin is regulated by the APP intracellular domain (AICD) (Pardossi-Piquard et al., 2005). To investigate whether reduction of neprilysin might be related to reduced levels of AICD in the nucleus with time in culture, we double labeled nuclei of 12 and 19 DIV AD-transgenic neurons with Hoechst stain and an AICD specific antibody. Remarkably, the number of AICD positive nuclei was decreased by 27±6% in 19 compared to 12 DIV AD-transgenic neurons (Figure 4B), suggesting reduced synthesis of neprilysin with time in culture.

Figure 4
Decreased levels of neprilysin in AD-transgenic neurons with time in culture. (A) Levels of neprilysin were decreased by 18±8% in 19 compared to 12 DIV AD- transgenic neurons (n=4; *p<0.05; scale bar 50 μm). In contrast, 19 compared ...

Discussion

The data presented here provide evidence for an impaired ability of familial AD- transgenic neurons to efficiently modulate levels of secreted and intraneuronal Aβ with time in culture. We demonstrate that the ability to secrete Aβ falls with time in culture in AD-transgenic but not wild-type neurons. Activity induced Aβ secretion also falls with time in culture in AD-transgenic but not wild-type neurons. Moreover, with time in culture AD-transgenic neurons become impaired in their ability to reduce intracellular Aβ and protect synapses in response to synaptic activity. We provide evidence that the mechanism by which synaptic activity reduces intracellular Aβ42 is dependent on the Aβ-degrading protease neprilysin. Synaptic activity leads to recruitment of neprilysin to the cell surface and increased co-localization with Aβ42. Finally, we show that neprilysin levels fall with time in culture in AD-transgenic but not wild-type neurons, providing a mechanism for the failure of synaptic activation to reduce intracellular Aβ in aged AD- transgenic neurons (Figure 4C, D).

These data have important implications for AD. Decreased neuronal secretion of Aβ with aging in AD could explain previous data that baseline interstitial Aβ42 levels appear to be reduced in older compared to younger AD-transgenic mice (Cirrito et al., 2005). Reduced Aβ42 levels are also seen in cerebrospinal fluid (CSF) in human AD, even in subjects who are cognitively normal but go on to develop AD (Fagan et al., 2009). The traditional explanation for reduced CSF Aβ42 with AD has been that secreted Aβ is decreased by sequestration to extracellular plaques. Decreased secretion would also contribute to reduced Aβ42 levels in CSF or interstitial fluid. Of note, other pathological conditions linked with AD, such as brain injury, also show reduced levels of extracellular Aβ (Brody et al., 2008) and increased intraneuronal Aβ (Gouras et al., 2010).

Reduced Aβ secretion fits well with increasing evidence for early intraneuronal Aβ accumulation with AD pathogenesis as now reported by many groups in human AD, Down syndrome, and in AD-transgenic rodents (Gouras et al., 2000; D’Andrea et al., 2001; Wirths et al., 2001; Takahashi et al., 2002; Oddo et al., 2003; Cataldo et al., 2004; Echeverria et al., 2004; Lord et al., 2006; Oakley et al., 2006; Knobloch et al., 2007; Gandy et al., 2010). Intraneuronal Aβ accumulates and oligomerizes preferentially in distal processes even prior to plaques (Takahashi et al., 2004), and is associated with memory impairment, decreased synaptic plasticity and subcellular pathology (Mori et al., 2002; Takahashi et al., 2002; Oddo et al., 2003; Almeida et al., 2005; Billings et al., 2005; Tomiyama et al., 2010). Intraneuronal Aβ42 localizes and accumulates preferentially in late endosomes, including multivesicular bodies (MVBs) (Takahashi et al., 2002; Langui et al., 2004; Almeida et al., 2006). Interestingly, neprilysin also localizes to late endosomes/MVBs (Figure 2E). We show that neprilysin significantly relocates to the cell surface during synaptic activation. Neprilysin is a transmembrane neutral endopeptidase with the catalytic site at the carboxy-terminal side, which can be either extracellular or luminal. Since neprilysin works best at neutral pH, the cell surface would be the optimal location for it to degrade Aβ42. In fact, we observed that colocalization of neprilysin and Aβ42 was increased at the cell surface with synaptic activation. This pool of Aβ42 could derive from amyloidogenic APP processing occurring within synaptic endosomes with synaptic activity (Cirrito et al., 2008; Tampellini et al., 2009), followed by trafficking of Aβ to the cell surface (Rajendran et al., 2006). The finding that neprilysin normally declines with aging in synaptic layers of wild-type mouse brain (Iwata et al., 2002) supports that it may play a critical role in synaptic accumulation of Aβ with aging and AD. We show that neprilysin is reduced in AD-transgenic but not wild-type neurons with time in culture, although it is possible that a decline would eventually occur later in wild-type neurons. Reduced neprilysin in AD- transgenic neurons with time in culture can explain the impaired ability to reduce intraneuronal Aβ, in particular Aβ42, with synaptic activity, since we previously reported the inability of synaptic activity to reduce Aβ42 in neprilysin knockout neurons or when neprilysin activity was blocked by treatment with thiorphan (Tampellini et al., 2009). In addition, it has been shown that extracellular Aβ can up-regulate intracellular Aβ (Yang et al., 1999; Tampellini et al., 2009), which could lead to a vicious cycle of Aβ-induced elevation and synapse damage.

Overall, this study provides novel evidence for reduced Aβ secretion and also impaired ability to reduce intraneuronal Aβ with time in culture in AD-transgenic neurons, and further underscores the important role of neprilysin in regulating neuronal Aβ.

Acknowledgments

Supported by an Alzheimer’s Association New Investigator Award (DT) and Zenith Award (GKG), National Institute of Health grants AG027140, AG028174, AG09464 (GKG), and AG020729 (MTL), and the Strong Research Environment Multipark (Multidisciplinary research in Parkinson’s disease at Lund University). The authors thank Fangmin Yu and Eleanor Reilly for technical support.

Footnotes

Conflict of interest: The authors declare that they have no conflict of interests.

References

  • Almeida CG, Takahashi RH, Gouras GK. Beta-amyloid accumulation impairs multivesicular body sorting by inhibiting the ubiquitin-proteasome system. J Neurosci. 2006;26:4277–4288. [PubMed]
  • Almeida CG, Tampellini D, Takahashi RH, Greengard P, Lin MT, Snyder EM, Gouras GK. Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses. Neurobiol Dis. 2005;20:187–198. [PubMed]
  • Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM. Intraneuronal Abeta causes the onset of early Alzheimer’s disease-related cognitive deficits in transgenic mice. Neuron. 2005;45:675–688. [PubMed]
  • Brody DL, Magnoni S, Schwetye KE, Spinner ML, Esparza TJ, Stocchetti N, Zipfel GJ, Holtzman DM. Amyloid-beta dynamics correlate with neurological status in the injured human brain. Science. 2008;321:1221–1224. [PMC free article] [PubMed]
  • Cataldo AM, Petanceska S, Terio NB, Peterhoff CM, Durham R, Mercken M, Mehta PD, Buxbaum J, Haroutunian V, Nixon RA. Abeta localization in abnormal endosomes: association with earliest Abeta elevations in AD and Down syndrome. Neurobiol Aging. 2004;25:1263–1272. [PubMed]
  • Cirrito JR, Kang JE, Lee J, Stewart FR, Verges DK, Silverio LM, Bu G, Mennerick S, Holtzman DM. Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron. 2008;58:42–51. [PMC free article] [PubMed]
  • Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtzman DM. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron. 2005;48:913–922. [PubMed]
  • Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci. 2005;8:79–84. [PubMed]
  • D’Andrea MR, Nagele RG, Wang HY, Peterson PA, Lee DH. Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer’s disease. Histopathology. 2001;38:120–134. [PubMed]
  • Echeverria V, Ducatenzeiler A, Dowd E, Janne J, Grant SM, Szyf M, Wandosell F, Avila J, Grimm H, Dunnett SB, Hartmann T, Alhonen L, Cuello AC. Altered mitogen-activated protein kinase signaling, tau hyperphosphorylation and mild spatial learning dysfunction in transgenic rats expressing the beta-amyloid peptide intracellularly in hippocampal and cortical neurons. Neuroscience. 2004;129:583–592. [PubMed]
  • Ehlers MD. Activity level controls postsynaptic composition and signaling via the ubiquitin-proteasome system. Nat Neurosci. 2003;6:231–242. [PubMed]
  • Fagan AM, Head D, Shah AR, Marcus D, Mintun M, Morris JC, Holtzman DM. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol. 2009;65:176–183. [PMC free article] [PubMed]
  • Gandy S, Simon AJ, Steele JW, Lublin AL, Lah JJ, Walker LC, Levey AI, Krafft GA, Levy E, Checler F, Glabe C, Bilker WB, Abel T, Schmeidler J, Ehrlich ME. Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-beta oligomers. Ann Neurol. 2010;68:220–230. [PMC free article] [PubMed]
  • Gouras GK, Tampellini D, Takahashi RH, Capetillo-Zarate E. Intraneuronal beta- amyloid accumulation and synapse pathology in Alzheimer’s disease. Acta Neuropathol. 2010;119:523–541. [PMC free article] [PubMed]
  • Gouras GK, Tsai J, Naslund J, Vincent B, Edgar M, Checler F, Greenfield JP, Haroutunian V, Buxbaum JD, Xu H, Greengard P, Relkin NR. Intraneuronal Abeta42 accumulation in human brain. Am J Pathol. 2000;156:15–20. [PubMed]
  • Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99–102. [PubMed]
  • Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, Sisodia S, Malinow R. AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron. 2006;52:831–843. [PMC free article] [PubMed]
  • Iwata N, Takaki Y, Fukami S, Tsubuki S, Saido TC. Region-specific reduction of A beta-degrading endopeptidase, neprilysin, in mouse hippocampus upon aging. J Neurosci Res. 2002;70:493–500. [PubMed]
  • Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R. APP processing and synaptic function. Neuron. 2003;37:925–937. [PubMed]
  • Knobloch M, Konietzko U, Krebs DC, Nitsch RM. Intracellular Abeta and cognitive deficits precede beta-amyloid deposition in transgenic arcAbeta mice. Neurobiol Aging. 2007;28:1297–1306. [PubMed]
  • Langui D, Girardot N, El Hachimi KH, Allinquant B, Blanchard V, Pradier L, Duyckaerts C. Subcellular topography of neuronal Abeta peptide in APPxPS1 transgenic mice. Am J Pathol. 2004;165:1465–1477. [PubMed]
  • Lord A, Kalimo H, Eckman C, Zhang XQ, Lannfelt L, Nilsson LN. The Arctic Alzheimer mutation facilitates early intraneuronal Abeta aggregation and senile plaque formation in transgenic mice. Neurobiol Aging. 2006;27:67–77. [PubMed]
  • Mori C, Spooner ET, Wisniewsk KE, Wisniewski TM, Yamaguch H, Saido TC, Tolan DR, Selkoe DJ, Lemere CA. Intraneuronal Abeta42 accumulation in Down syndrome brain. Amyloid. 2002;9:88–102. [PubMed]
  • Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, Berry R, Vassar R. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006;26:10129–10140. [PubMed]
  • Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003;39:409–421. [PubMed]
  • Palop JJ, Mucke L. Amyloid-beta-induced neuronal dysfunction in Alzheimer’s disease: from synapses toward neural networks. Nat Neurosci. 2010;13:812–818. [PMC free article] [PubMed]
  • Pardossi-Piquard R, Petit A, Kawarai T, Sunyach C, Alves da Costa C, Vincent B, Ring S, D’Adamio L, Shen J, Muller U, St George Hyslop P, Checler F. Presenilin-dependent transcriptional control of the Abeta-degrading enzyme neprilysin by intracellular domains of betaAPP and APLP. Neuron. 2005;46:541–554. [PubMed]
  • Puzzo D, Privitera L, Leznik E, Fa M, Staniszewski A, Palmeri A, Arancio O. Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. J Neurosci. 2008;28:14537–14545. [PMC free article] [PubMed]
  • Rajendran L, Honsho M, Zahn TR, Keller P, Geiger KD, Verkade P, Simons K. Alzheimer’s disease beta-amyloid peptides are released in association with exosomes. Proc Natl Acad Sci U S A. 2006;103:11172–11177. [PubMed]
  • Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, Saunders AM, Hardy J. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer’s dementia. Proc Natl Acad Sci U S A. 2004;101:284–289. [PubMed]
  • Selkoe DJ. Alzheimer’s disease is a synaptic failure. Science. 2002;298:789–791. [PubMed]
  • Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ. Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat Med. 2008;14:837–842. [PMC free article] [PubMed]
  • Takahashi RH, Almeida CG, Kearney PF, Yu F, Lin MT, Milner TA, Gouras GK. Oligomerization of Alzheimer’s beta-amyloid within processes and synapses of cultured neurons and brain. J Neurosci. 2004;24:3592–3599. [PubMed]
  • Takahashi RH, Milner TA, Li F, Nam EE, Edgar MA, Yamaguchi H, Beal MF, Xu H, Greengard P, Gouras GK. Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol. 2002;161:1869–1879. [PubMed]
  • Tampellini D, Capetillo-Zarate E, Dumont M, Huang Z, Yu F, Lin MT, Gouras GK. Effects of Synaptic Modulation on {beta}-Amyloid, Synaptophysin, and Memory Performance in Alzheimer’s Disease Transgenic Mice. J Neurosci. 2010;30:14299–14304. [PMC free article] [PubMed]
  • Tampellini D, Rahman N, Gallo EF, Huang Z, Dumont M, Capetillo-Zarate E, Ma T, Zheng R, Lu B, Nanus DM, Lin MT, Gouras GK. Synaptic activity reduces intraneuronal Abeta, promotes APP transport to synapses, and protects against Abeta-related synaptic alterations. J Neurosci. 2009;29:9704–9713. [PMC free article] [PubMed]
  • Tomiyama T, Matsuyama S, Iso H, Umeda T, Takuma H, Ohnishi K, Ishibashi K, Teraoka R, Sakama N, Yamashita T, Nishitsuji K, Ito K, Shimada H, Lambert MP, Klein WL, Mori H. A mouse model of amyloid {beta} oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J Neurosci. 2010;30:4845–4856. [PubMed]
  • Wirths O, Multhaup G, Czech C, Blanchard V, Moussaoui S, Tremp G, Pradier L, Beyreuther K, Bayer TA. Intraneuronal Abeta accumulation precedes plaque formation in beta-amyloid precursor protein and presenilin-1 double- transgenic mice. Neurosci Lett. 2001;306:116–120. [PubMed]
  • Yang AJ, Chandswangbhuvana D, Shu T, Henschen A, Glabe CG. Intracellular accumulation of insoluble, newly synthesized abetan-42 in amyloid precursor protein-transfected cells that have been treated with Abeta1-42. J Biol Chem. 1999;274:20650–20656. [PubMed]